Evaluation of simvastatin combined with ezetimibe on therapy of lowing blood lipids in metabolic syndrome patients
10.3760/cma.j.issn.1008-6315.2012.07.010
- VernacularTitle:代谢综合征患者辛伐他汀联合依折麦布降血脂治疗的评价
- Author:
Zhonghua CUI
;
Xijuan ZHANG
;
Yongmei LI
;
Shuang LIU
;
Xiaodan HU
;
Yanxin ZHAO
- Publication Type:Journal Article
- Keywords:
Simvastatin;
Ezetimibe;
Metabolic syndrome;
Cardiovascular and cerebrovascular events
- From:
Clinical Medicine of China
2012;28(7):701-703
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy,adverse effect and the incidence of cardiovascular and cerebrovascular events by comparative study on simvastatin combined with ezetimibe on therapy of lowing blood lipids in metabolic syndrome patients.Methods One hundred and twenty metabolic syndrome patients were divided into experiment group (n=60) and control group (n=60).The experiment group was treated with 20 mg of simvastatin associated 10 mg of ezetimibe daily.The control group was treated with conventional-dose 20 mg of simvastatin.The period of treatment was 4 years in both groups.The efficacy,adverse effect and the occurrence of cardiovascular and cerebrovascular events were observed and analyzed.Results Blood lipid were significantly decreased in both groups after the treatment.There was significant difference on total cholesterol ( TC ) [ ( 3.05±1.17 ) mmol/L vs (4.94 ± 1.13 ) mmol/L,P ＜ 0.05 ],low density lipoprotein cholesterol ( LDLC) [ (2.12±1.03) mmol/L vs (3.16 ± 1.11 ) mmol/L,P ＜0.05] and triglyceride(TC) (1.02±0.29) mmol/Lvs (1.65 ± 0.32)mmol/L,P ＜ 0.05 ) between experiment group and control group.There were 3 cases of cardiovascular events in experiment group and 10 cases in control group,5 cases of cerebrovascular events in experiment group and 13 cases in control group.The incidence of cardiovascular and cerebrovascular in experiment group was significantly lower than that in control group (x2 =4.08 and 4.37,respectively,P ＜ 0.05 ).Conclusion Combination therapy with simvastatin and ezetimibe is more effective and it can significantly decrease the incidence of cardiovascular and cerebrovascular events in metabolic syndrome patients.
